Novo Competitors

Pink Sheets . USA . 
Stock . Novo Nordisk AS
NONOF Stock  USD 109.00  0.70  0.64%   
Novo Nordisk AS competes with Sino Biopharmaceutica, Defence Therapeutics, Aileron Therapeutics, and Enlivex Therapeutics; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Novo Nordisk competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Novo Nordisk to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Novo Nordisk Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Novo Nordisk competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
106.52109.00111.48
Details
Intrinsic
Valuation
LowRealHigh
98.89101.37119.90
Details
Naive
Forecast
LowNextHigh
107.76110.24112.72
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
97.80113.67129.53
Details

Novo Nordisk Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Novo Nordisk and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Novo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Novo Nordisk AS does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RGBP
+ 0.56
ENLV
RGBP
+ 0.52
ALRN
ENLV
+ 0.51
ALRN
LVCLF
+ 0.42
DTCFF
RGBP
+ 0.26
MRZM
MRZM
+ 0.2
ENLV
  
High negative correlations   
LVCLF
- 0.56
SBHMY
ENLV
- 0.53
SBHMY
DTCFF
- 0.23
SBHMY
LVCLF
- 0.2
ALRN
RGBP
- 0.19
LVCLF
MRZM
- 0.1
LVCLF

Risk-Adjusted Indicators

There is a big difference between Novo Pink Sheet performing well and Novo Nordisk Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Novo Nordisk's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SBHMY  0.64  0.21  0.00  1.46  0.00 
 0.00 
 0.00 
 0.00 
 25.86 
DTCFF  1.04 (0.15) 0.00  1.03  0.00 
 0.00 
 0.00 
(2.44)
 25.87 
ALRN  4.30 (0.28) 0.00 (0.36) 0.00 
 0.00 
 8.06 
(8.77)
 41.47 
ENLV  3.93  0.01  0.01  0.12  3.97 
(5.57)
 10.71 
(6.15)
 35.66 
LVCLF  1.99 (0.50) 0.00 (0.37) 0.00 
 0.00 
 0.00 
 0.00 
 66.02 
MCET  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
HESG  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MYMX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MRZM  8.10  1.93  0.04 (0.47) 9.60 
(55.00)
 25.00 
(20.00)
 128.57 
RGBP  26.74  5.57  0.19  7.03  22.54 
(38.78)
 100.00 
(47.83)
 196.39 
All Fundamental Data

Novo Nordisk Competitive Analysis

The better you understand Novo Nordisk competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Novo Nordisk's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Novo Nordisk's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NONOF SBHMY DTCFF ALRN ENLV LVCLF MYMX MRZM RGBP
 0.64 
 109.00 
Novo
 0.00 
 9.05 
Sino
 0.00 
 0.41 
Defence
 2.34 
 2.19 
Aileron
 2.34 
 1.25 
Enlivex
 18.60 
 0.01 
Living
 0.00 
 0 
Mymetics
 20.00 
 0.04 
Marizyme
 31.82 
 0.07 
Regen
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Out of control
Slightly risky
Risky
Out of control
Very steady
Out of control
Out of control
Market Performance
(90 Days Performance)
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Modest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Very High
About Average
Low
Low
Quite High
Below Average
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Current Ratio
0.94
1.55
0.61
6.51
15.44
17.84
0.01
1.74
0.05
Net Asset
241.26 B
60.54 B
719.67 K
106.01 M
36.83 M
4.27 M
7.63 M
66 M
559 K
Profit Margin
0.31
0.29
N/A
N/A
N/A
N/A
N/A
N/A
6.09
EBITDA
76.8 B
19.87 B
(7.32 M)
(15.61 M)
(28.22 M)
(2.38 M)
(1.96 M)
(10.83 M)
2.44 M
Operating Margin
0.43
0.16
N/A
N/A
N/A
-428.7
-1.76
-180.85
-2.96
Current Valuation
292.82 B
10.34 B
60.32 M
30.4 M
4.41 M
12.53 M
83.16 M
17.35 M
22.4 M
Price To Book
26.64
2.53
36.71
0.95
1.06
6.96
N/A
0.37
N/A
Retained Earnings
41.06 B
N/A
N/A
(288.52 M)
(112.09 M)
(67 M)
(81.98 M)
N/A
(17.78 M)
Current Asset
51.58 B
N/A
N/A
3.43 M
6 M
6 M
1.38 M
N/A
171 K
Five Year Return
1.78
0.99
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.33
0.51
N/A
2.34
1.11
0.27
0.24
0.36
3.36
Number Of Employees
54.39 K
25.55 K
4
15
N/A
15
9
11
1
Shares Outstanding
1.72 B
940.69 M
37.85 M
21.67 M
21.99 M
1.29 B
303.76 M
10.13 M
5.05 B
Cash Flow From Operations
78.89 B
5.37 B
(6.04 M)
(19.81 M)
(23.52 M)
(2.04 M)
(1.7 M)
(5.79 M)
(606.92 K)
Annual Yield
0.0115
0.0265
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
20.77 B
5.21 B
N/A
48 K
1.03 M
228.44 K
162 K
495.32 K
1.58 M
Return On Equity
0.72
0.29
-4.15
-0.44
-0.61
-0.72
N/A
-0.5
N/A
Z Score
9.0
1.2
-33.0
N/A
N/A
5.4
-1.4
6.0
-26.6
Return On Asset
0.22
0.0451
-1.79
-0.26
-0.27
-0.31
-0.14
-0.15
-0.76
Book Value Per Share
37.1
32.7
-0.025
1.41
1.62
0.003
-0.21
1.0
-0.001
Number Of Shares Shorted
N/A
N/A
N/A
180.73 K
99.23 K
N/A
N/A
N/A
N/A
Current Liabilities
41.59 B
N/A
N/A
459 K
671.32 K
1000 K
51.24 M
N/A
649 K
Total Asset
241.26 B
60.54 B
719.67 K
106.01 M
36.83 M
4.27 M
7.63 M
66 M
559 K
Debt To Equity
0.34
0.31
N/A
0.003
0.077
0.1
N/A
0.066
1.25
Last Dividend Paid
12.4
0.083
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
N/A
N/A
3.47
0.56
N/A
N/A
N/A
N/A
Target Price
N/A
N/A
N/A
13.0
9.5
N/A
N/A
N/A
N/A
Shares Owned By Institutions
38.87
N/A
N/A
28.47
18.8
N/A
N/A
N/A
N/A
Market Capitalization
318.05 B
10.88 B
143.45 M
45.93 M
27.49 M
9.81 M
5.47 M
5.07 M
10.1 M
Price To Earning
41.24
8.95
N/A
-0.31
-11.97
-31.67
-2.4
N/A
N/A
Price To Earnings To Growth
1.94
0.53
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
1.73
0.41
N/A
N/A
N/A
5586.88
12.17
133.06
89.73
Net Income
55.52 B
14.61 B
(7.34 M)
(15.73 M)
(29.07 M)
(1.96 M)
(4.73 M)
(11 M)
2.44 M
Earnings Per Share
3.53
1.15
-0.15
-2.88
-0.98
-0.002
-0.016
-0.38
N/A
Shares Owned By Insiders
N/A
N/A
5.26
0.6
5.73
33.99
54.9
2.04
0.06
Revenue
176.95 B
26.86 B
N/A
N/A
N/A
3.4 K
3 K
210.28 K
235.52 K
Working Capital
9.98 B
N/A
N/A
13.88 M
27.7 M
5 M
(49.86 M)
N/A
(478 K)
Cash And Equivalents
31.04 B
15.67 B
506.7 K
32.38 M
62.48 M
4.24 M
350 K
2.04 M
110.99 K
Cash Per Share
13.68
16.96
0.01
0.36
3.4
N/A
N/A
0.05
N/A
Gross Profit
148.51 B
21.53 B
N/A
(17.01 M)
N/A
3.4 K
(545 K)
129.93 K
235.52 K
Day Typical Price
109.0
9.05
0.41
2.17
1.26
0.0051
0.001
0.04
0.075
Accumulation Distribution
N/A
N/A
N/A
0.032
0.0465
N/A
N/A
N/A
N/A
Market Facilitation Index
N/A
N/A
N/A
0.07
0.06
N/A
N/A
N/A
N/A
Daily Balance Of Power
(9,223,372,036,855)
0.0
0.0
0.7143
(0.50)
9.2 T
0.0
(9,223,372,036,855)
(9,223,372,036,855)
Period Momentum Indicator
(0.70)
N/A
N/A
0.05
(0.03)
8.0E-4
N/A
(0.01)
(0.04)
Rate Of Daily Change
0.99
1.0
1.0
1.02
0.98
1.19
1.0
0.8
0.68
Day Median Price
109.0
9.05
0.41
2.16
1.26
0.0051
0.001
0.04
0.075
Price Action Indicator
(0.35)
N/A
N/A
0.06
(0.03)
4.0E-4
N/A
(0.01)
(0.02)
Relative Strength Index
41.67
69.02
52.56
32.37
40.21
27.8
N/A
48.99
42.13
Coefficient Of Variation
(1,077)
1132.0
(2,085)
(3,038)
3403.44
(2,408)
N/A
1251.52
691.44
Mean Deviation
1.99
0.6415
1.04
4.3
3.93
1.99
N/A
8.1
26.74
Jensen Alpha
(0.31)
0.2053
(0.15)
(0.28)
0.0131
(0.50)
N/A
1.93
5.57
Total Risk Alpha
(0.65)
(0.19)
(0.68)
(1.18)
(0.76)
(1.80)
N/A
(1.55)
(0.55)
Sortino Ratio
N/A
N/A
N/A
N/A
0.0107
N/A
N/A
0.0429
0.1911
Downside Variance
N/A
N/A
N/A
N/A
19.23
N/A
N/A
1125.49
841.76
Standard Deviation
2.53
2.64
3.22
6.13
5.84
8.96
N/A
19.55
39.2
Kurtosis
0.0015
57.69
15.33
6.01
4.18
46.58
N/A
12.93
2.24
Potential Upside
4.23
N/A
N/A
8.06
10.71
N/A
N/A
25.0
100.0
Treynor Ratio
(0.43)
1.46
1.03
(0.36)
0.1245
(0.37)
N/A
(0.47)
7.03
Maximum Drawdown
12.29
25.86
25.87
41.47
35.66
66.02
N/A
128.57
196.39
Variance
6.41
6.94
10.39
37.62
34.09
80.28
N/A
382.18
1536.7
Market Risk Adjusted Performance
(0.42)
1.47
1.04
(0.35)
0.1345
(0.36)
N/A
(0.46)
7.04
Risk Adjusted Performance
(0.06)
0.0711
(0.03)
(0.01)
0.03
(0.02)
N/A
0.0673
0.1143
Skewness
(0.09)
7.21
(0.39)
1.43
1.5
(5.81)
N/A
2.66
1.27
Semi Deviation
N/A
N/A
N/A
N/A
3.97
N/A
N/A
9.6
22.54
Information Ratio
(0.14)
0.0411
(0.09)
(0.05)
0.0081
(0.06)
N/A
0.0735
0.1415
Value At Risk
(4.53)
N/A
(2.44)
(8.77)
(6.15)
N/A
N/A
(20.00)
(47.83)
Expected Short fall
N/A
N/A
N/A
N/A
(5.57)
N/A
N/A
(55.00)
(38.78)
Downside Deviation
N/A
N/A
N/A
N/A
4.38
N/A
N/A
33.55
29.01
Semi Variance
N/A
N/A
N/A
N/A
15.77
N/A
N/A
92.2
508.01

Novo Nordisk Competition Performance Charts

Five steps to successful analysis of Novo Nordisk Competition

Novo Nordisk's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Novo Nordisk AS in relation to its competition. Novo Nordisk's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Novo Nordisk in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Novo Nordisk's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Novo Nordisk AS, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Novo Nordisk position

In addition to having Novo Nordisk in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities - Regulated Electric Thematic Idea Now

Utilities - Regulated Electric
Utilities - Regulated Electric Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities - Regulated Electric theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities - Regulated Electric Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Novo Pink Sheet

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
How To Invest In Novo
Details
Is Novo Pink Sheet a good investment?
Details
What is Novo Nordisk's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Novo Nordisk Correlation with its peers.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY